The role of TP53 in acute myeloid leukemia: Challenges and ...
In patients with TP53 mutations, these alterations may lead to novel, selective vulnerabilities, creating opportunities for therapeutic targeting of TP53 mutant AML. The mutational status of …
TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns …
2021年10月5日 · Mutation of the tumor suppressor gene, TP53, is associated with abysmal survival outcomes in acute myeloid leukemia (AML). Although it is the most commonly …
TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited
The most common mutations in acute myeloid leukemia (AML) occur in the DNA-binding domain of p53. TP53 mutations are associated with a very poor prognosis and define a unique disease …
TP53 Mutations in Acute Leukemias and Myelodysplastic …
2024年5月20日 · TP53 mutations are found in 5%-10% of de novo myelodysplastic syndrome (MDS) and AML cases. By contrast, in therapy related MDS and AML, mutations in TP53 are …
p53 pathway dysfunction is highly prevalent in acute myeloid leukemia ...
2016年11月25日 · TP53 mutations are associated with the lowest survival rates in acute myeloid leukemia (AML). In addition to mutations, loss of p53 function can arise via aberrant …
Survival of TP53-mutated acute myeloid leukemia patients
2023年2月18日 · TP53 mutated (m) acute myeloid leukemia (AML) is associated with high relapse rate and poor overall survival (OS) [1, 2, 3]. Response to cytotoxic chemotherapy is highly …
What have we learned about TP53- mutated acute myeloid leukemia…
2024年11月19日 · TP53 mutations are found in approximately 5% to 10% of patients with de novo acute myeloid leukemia (AML), more frequently observed in elderly patients and those with …
The role of p53 in myelodysplastic syndromes and acute myeloid leukemia ...
TP53 gene mutations occurring in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are associated with high-risk karyotypes including 17p abnormalities, …
【BCJ】我们从TP53突变AML中学到了什么？ - MedSci
2024年12月26日 · 《Blood Cancer Journal》近日发表综述，全面概述了 AML 中的 TP53 突变、基于等位基因负荷的结局、临床意义、治疗挑战和改善长期预后的策略。 TP53 基因也称为基 …
靶向p53癌症治疗药物的研究进展：从分子机制到临床转化
2025年3月2日 · 在难治性复发性AML和CML患者中，RG7112可触发wtp53激活，并提高许多p53靶基因的表达，在许多患者中观察到RG7112的抗白血病活性。 然而，需要大剂量的RG7112才 …